Literature DB >> 27892948

Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).

N Shah1, S Rauenzahn2, L Veltri1, S Wen3, M Craig1, M Hamadani4, A S Kanate1, A Cumpston1,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27892948     DOI： 10.1038/bmt.2016.275

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.

Authors:  A G McCoy; E P Smith; M E Atkinson; B Baranski; B S Kahl; M Juckett; T Mitchell; R Gangnon; W L Longo
Journal:  Bone Marrow Transplant       Date:  2004-01       Impact factor: 5.483

2.  BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.

Authors:  M D Caballero; V Rubio; J Rifon; I Heras; R García-Sanz; L Vázquez; B Vidriales; M C del Cañizo; M Corral; M Gonzalez; A León; E Jean-Paul; E Rocha; J M Moraleda; J F San Miguel
Journal:  Bone Marrow Transplant       Date:  1997-09       Impact factor: 5.483

Review 3.  Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.

Authors:  Vijaya Raj Bhatt; Julie M Vose
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-22       Impact factor: 3.722

4.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

5.  Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.

Authors:  C Wheeler; J H Antin; W H Churchill; S E Come; B R Smith; G J Bubley; D S Rosenthal; J M Rappaport; K A Ault; L E Schnipper
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

6.  Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: Long-term autologous transplantation experience in follicular and mantle cell lymphoma.

Authors:  Timothy S Fenske; Brad S Kahl; Jens Eickhoff; Teri L Mitchell; Eileen P Smith; Elizabeth Atkinson; Alice Garry McCoy; Linda Eckstein; Bridget Flynn; Jan McMannes; Steven Howard; Walter L Longo
Journal:  Leuk Lymphoma       Date:  2005-10

7.  High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.

Authors:  K Schiffman; C D Buckner; R Maziarz; D G Maloney; F R Appelbaum; O Press; T Gooley; L Holmberg; K Lilleby; R Clift; N Zuckerman; J Klarnet; C Weaver; T Chauncey; W I Bensinger
Journal:  Biol Blood Marrow Transplant       Date:  1997-11       Impact factor: 5.742

Review 8.  High-dose chemotherapy regimens for solid tumors.

Authors:  E van der Wall; J H Beijnen; S Rodenhuis
Journal:  Cancer Treat Rev       Date:  1995-03       Impact factor: 12.111

9.  Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

Authors:  L Sellner; A Boumendil; H Finel; S Choquet; G de Rosa; F Falzetti; R Scime; G Kobbe; F Ferrara; A Delmer; H Sayer; S Amorim; R Bouabdallah; J Finke; G Salles; I Yakoub-Agha; E Faber; E Nicolas-Virelizier; L Facchini; D Vallisa; E Zuffa; A Sureda; P Dreger
Journal:  Bone Marrow Transplant       Date:  2015-11-16       Impact factor: 5.483

10.  Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.

Authors:  Yi-Bin Chen; Tracy Batchelor; Shuli Li; Ephraim Hochberg; Mark Brezina; Sooae Jones; Candice Del Rio; Morgan Curtis; Karen K Ballen; Jeffrey Barnes; Andrew S Chi; Jorg Dietrich; Jessica Driscoll; Elizabeth R Gertsner; Fred Hochberg; Ann S LaCasce; Steven L McAfee; Thomas R Spitzer; Lakshmi Nayak; Philippe Armand
Journal:  Cancer       Date:  2014-09-09       Impact factor: 6.860
View more
  1 in total

1.  Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Authors:  Alison J Moskowitz; Heiko Schöder; Somali Gavane; Katie L Thoren; Martin Fleisher; Joachim Yahalom; Susan J McCall; Briana R Cadzin; Stephanie Y Fox; John Gerecitano; Ravinder Grewal; Paul A Hamlin; Steven M Horwitz; Anita Kumar; Matthew Matasar; Andy Ni; Ariela Noy; M Lia Palomba; Miguel-Angel Perales; Carol S Portlock; Craig Sauter; David Straus; Anas Younes; Andrew D Zelenetz; Craig H Moskowitz
Journal:  Blood       Date:  2017-09-05       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.